---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-005077"
form_type: "8-K"
ticker: "RGNX"
cik: "0001590877"
company_name: "REGENXBIO Inc."
filed_at: "2023-02-28T23:59:59+00:00"
generated_at: "2026-06-18T22:10:12.803908+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# REGENXBIO Q4 net loss $59.9M ($1.38/share); revenue $31.3M vs $398.7M YoY; cash $565M

## Summary
- Full-year 2022 net loss $280.3M ($6.50/share) vs net income $127.8M in 2021.
- Revenue fell to $112.7M in 2022 from $470.3M, driven by $370M non-recurring AbbVie collaboration revenue in 2021.
- Zolgensma royalties rose to $101.9M in 2022 from $95.0M in 2021.
- Cash, equivalents and marketable securities $565.2M as of Dec 31, 2022, down from $849.3M; runway into 2025.
- RGX-314 pivotal trials ongoing with BLA expected in 2024; RGX-121 pivotal enrollment to complete H1 2023.

## SEC filing metadata
- accession: 0000950170-23-005077
- form_type: 8-K
- ticker: RGNX
- cik: 0001590877
- company_name: REGENXBIO Inc.
- filed_at: 2023-02-28T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1590877/000095017023005077/0000950170-23-005077-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1590877/000095017023005077/rgnx-20230228.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-005077
- JSON: https://secwatch.observer/filing/0000950170-23-005077.json
- Plain text: https://secwatch.observer/filing/0000950170-23-005077.txt

## Key facts
- Earnings Releases
  REGENXBIO Inc. reported financial results for the quarter and year ended December 31, 2022.
  - Period: the quarter and year ended December 31, 2022
  - Result: reported results
  source text: On February 28, 2023, REGENXBIO Inc. (the “Company”) issued a press release regarding its results of operations and financial condition for the quarter and year ended December 31, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1590877/000095017023005077/0000950170-23-005077-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.